JPS628433B2 - - Google Patents
Info
- Publication number
- JPS628433B2 JPS628433B2 JP57192620A JP19262082A JPS628433B2 JP S628433 B2 JPS628433 B2 JP S628433B2 JP 57192620 A JP57192620 A JP 57192620A JP 19262082 A JP19262082 A JP 19262082A JP S628433 B2 JPS628433 B2 JP S628433B2
- Authority
- JP
- Japan
- Prior art keywords
- ergoline
- methyl
- group
- formula
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- -1 Ergoline amine Chemical class 0.000 claims description 4
- 230000001262 anti-secretory effect Effects 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 230000000767 anti-ulcer Effects 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
- ILVSIAOVMVETCC-NYSBEXSLSA-N n-[[(6ar,9s,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]benzamide Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)NC(=S)NC(=O)C1=CC=CC=C1 ILVSIAOVMVETCC-NYSBEXSLSA-N 0.000 claims description 3
- RAQHJMIGHPUZCG-XGWLTEMNSA-N n-[[(6ar,9s,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamoyl]acetamide Chemical compound C1=CC([C@H]2C[C@@H](CNC(=O)NC(C)=O)CN([C@@H]2C2)C)=C3C2=CNC3=C1 RAQHJMIGHPUZCG-XGWLTEMNSA-N 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 238000002844 melting Methods 0.000 description 26
- 230000008018 melting Effects 0.000 description 26
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 15
- IXCCQSTVBSTCLP-PSOPSSQASA-N [(6ar,9s,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methanamine Chemical compound C1=CC([C@H]2C[C@@H](CN)CN([C@@H]2C2)C)=C3C2=CNC3=C1 IXCCQSTVBSTCLP-PSOPSSQASA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- IXCCQSTVBSTCLP-RIEGTJTDSA-N [(6ar,9r,10as)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methanamine Chemical compound C1=CC([C@@H]2C[C@H](CN)CN([C@@H]2C2)C)=C3C2=CNC3=C1 IXCCQSTVBSTCLP-RIEGTJTDSA-N 0.000 description 5
- VITFJKNVGRZRKB-UHFFFAOYSA-N acetyl isothiocyanate Chemical compound CC(=O)N=C=S VITFJKNVGRZRKB-UHFFFAOYSA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- OCKPROYBCPQWJO-UHFFFAOYSA-N acetyl isocyanate Chemical compound CC(=O)N=C=O OCKPROYBCPQWJO-UHFFFAOYSA-N 0.000 description 3
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 3
- 230000001078 anti-cholinergic effect Effects 0.000 description 3
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 description 3
- 229960002474 hydralazine Drugs 0.000 description 3
- SLLROHIXDLFZRW-IHLLOCCUSA-N C(CC)N1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=O)NC(C1=CC=CC=C1)=O Chemical compound C(CC)N1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=O)NC(C1=CC=CC=C1)=O SLLROHIXDLFZRW-IHLLOCCUSA-N 0.000 description 2
- XPIHBSNJNOUVNN-UQIDSAAFSA-N CN1C=C2C[C@H]3N(C[C@@H](C[C@@H]3C=3C=CC=C1C=32)CNC(=N)NC(C1=CN=CC(=C1)Br)=O)C Chemical compound CN1C=C2C[C@H]3N(C[C@@H](C[C@@H]3C=3C=CC=C1C=32)CNC(=N)NC(C1=CN=CC(=C1)Br)=O)C XPIHBSNJNOUVNN-UQIDSAAFSA-N 0.000 description 2
- VHRQJLMIRPMSSM-BSLALVQMSA-N CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=O)NC(C1=CC=CC=C1)=O Chemical compound CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=O)NC(C1=CC=CC=C1)=O VHRQJLMIRPMSSM-BSLALVQMSA-N 0.000 description 2
- OMTGUYWJRZTRPX-SAWYMBPVSA-N CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C Chemical compound CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C OMTGUYWJRZTRPX-SAWYMBPVSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XYHGVICXPBRDJB-XNRPHZJLSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]carbamothioyl]acetamide Chemical compound C1=CC([C@H]2C[C@H](CN([C@@H]2C2)C)NC(=S)NC(C)=O)=C3C2=CNC3=C1 XYHGVICXPBRDJB-XNRPHZJLSA-N 0.000 description 2
- NAGWTFIBSQGMEA-YVWKXTFCSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]carbamothioyl]benzamide Chemical compound N([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C(=S)NC(=O)C1=CC=CC=C1 NAGWTFIBSQGMEA-YVWKXTFCSA-N 0.000 description 2
- MSWCMKXRLBZTLQ-XNRPHZJLSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]carbamoyl]acetamide Chemical compound C1=CC([C@H]2C[C@H](CN([C@@H]2C2)C)NC(=O)NC(C)=O)=C3C2=CNC3=C1 MSWCMKXRLBZTLQ-XNRPHZJLSA-N 0.000 description 2
- SDMGECXXTHFQTB-YVWKXTFCSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]carbamoyl]benzamide Chemical compound N([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C(=O)NC(=O)C1=CC=CC=C1 SDMGECXXTHFQTB-YVWKXTFCSA-N 0.000 description 2
- VNRVWDFBQJATNK-SRCQZFHVSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]acetamide Chemical compound C1=CC([C@H]2C[C@H](CNC(=S)NC(C)=O)CN([C@@H]2C2)C)=C3C2=CNC3=C1 VNRVWDFBQJATNK-SRCQZFHVSA-N 0.000 description 2
- ILVSIAOVMVETCC-QFIXIFRTSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]benzamide Chemical compound C([C@@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)NC(=S)NC(=O)C1=CC=CC=C1 ILVSIAOVMVETCC-QFIXIFRTSA-N 0.000 description 2
- RAQHJMIGHPUZCG-SRCQZFHVSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamoyl]acetamide Chemical compound C1=CC([C@H]2C[C@H](CNC(=O)NC(C)=O)CN([C@@H]2C2)C)=C3C2=CNC3=C1 RAQHJMIGHPUZCG-SRCQZFHVSA-N 0.000 description 2
- BNTOYYSKEDTQHC-QFIXIFRTSA-N n-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamoyl]benzamide Chemical compound C([C@@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)NC(=O)NC(=O)C1=CC=CC=C1 BNTOYYSKEDTQHC-QFIXIFRTSA-N 0.000 description 2
- ILVSIAOVMVETCC-MFMILTCTSA-N n-[[(6ar,9r,10as)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]benzamide Chemical compound C([C@@H]1CN([C@H]2[C@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)NC(=S)NC(=O)C1=CC=CC=C1 ILVSIAOVMVETCC-MFMILTCTSA-N 0.000 description 2
- BNTOYYSKEDTQHC-MFMILTCTSA-N n-[[(6ar,9r,10as)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamoyl]benzamide Chemical compound C([C@@H]1CN([C@H]2[C@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)NC(=O)NC(=O)C1=CC=CC=C1 BNTOYYSKEDTQHC-MFMILTCTSA-N 0.000 description 2
- BLFSQTRAKPYQPF-FDQGKXFDSA-N n-[[(6ar,9s,10ar)-5,7-dimethyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamoyl]acetamide Chemical compound C1=CC([C@H]2C[C@@H](CNC(=O)NC(C)=O)CN([C@@H]2C2)C)=C3C2=C(C)NC3=C1 BLFSQTRAKPYQPF-FDQGKXFDSA-N 0.000 description 2
- FFKNCEFGDNXKSB-NORZTCDRSA-N n-[[(6ar,9s,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamoyl]acetamide Chemical compound C1=CC([C@H]2C[C@@H](CNC(=O)NC(C)=O)CN([C@@H]2C2)C)=C3C2=C(Br)NC3=C1 FFKNCEFGDNXKSB-NORZTCDRSA-N 0.000 description 2
- VNRVWDFBQJATNK-XGWLTEMNSA-N n-[[(6ar,9s,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]acetamide Chemical compound C1=CC([C@H]2C[C@@H](CNC(=S)NC(C)=O)CN([C@@H]2C2)C)=C3C2=CNC3=C1 VNRVWDFBQJATNK-XGWLTEMNSA-N 0.000 description 2
- RHAIURMONFOUQK-XGWLTEMNSA-N n-[[(6ar,9s,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]propanamide Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)CNC(=S)NC(=O)CC)=C3C2=CNC3=C1 RHAIURMONFOUQK-XGWLTEMNSA-N 0.000 description 2
- BNTOYYSKEDTQHC-NYSBEXSLSA-N n-[[(6ar,9s,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methylcarbamoyl]benzamide Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)NC(=O)NC(=O)C1=CC=CC=C1 BNTOYYSKEDTQHC-NYSBEXSLSA-N 0.000 description 2
- HHCKTOFYOWCMNU-HLLQZAQXSA-N n-[[(6ar,9s,10as)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6h-indolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]acetamide Chemical compound C1=CC([C@]2(OC)[C@H](N(C)C[C@H](CNC(=S)NC(C)=O)C2)C2)=C3C2=CN(C)C3=C1 HHCKTOFYOWCMNU-HLLQZAQXSA-N 0.000 description 2
- UTSKBPNFLFYTAH-ZLXGRDSLSA-N n-[[(6ar,9s,10as)-10a-methoxy-7-methyl-4,6,6a,8,9,10-hexahydroindolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]acetamide Chemical compound C1=CC([C@]2(OC)[C@H](N(C)C[C@H](CNC(=S)NC(C)=O)C2)C2)=C3C2=CNC3=C1 UTSKBPNFLFYTAH-ZLXGRDSLSA-N 0.000 description 2
- BDDWRAKMTHJXMW-NYSBEXSLSA-N n-[n'-[[(6ar,9r,10ar)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-yl]methyl]carbamimidoyl]pyridine-3-carboxamide Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)N=C(N)NC(=O)C1=CC=CN=C1 BDDWRAKMTHJXMW-NYSBEXSLSA-N 0.000 description 2
- VJTJZROLTOSWIE-XGWLTEMNSA-N n-[n'-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methyl]carbamimidoyl]acetamide Chemical compound C1=CC([C@H]2C[C@@H](CN=C(N)NC(C)=O)CN([C@@H]2C2)C)=C3C2=CNC3=C1 VJTJZROLTOSWIE-XGWLTEMNSA-N 0.000 description 2
- QOFTVRKKQGHHQV-NYSBEXSLSA-N n-[n'-[[(6ar,9r,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methyl]carbamimidoyl]benzamide Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)N=C(N)NC(=O)C1=CC=CC=C1 QOFTVRKKQGHHQV-NYSBEXSLSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UNELDXFWWQRODL-IUODEOHRSA-N (6ar,10ar)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2CCCN([C@@H]2C2)C)=C3C2=CN(C)C3=C1 UNELDXFWWQRODL-IUODEOHRSA-N 0.000 description 1
- ZYACKOKSHZQYDS-NTVGDFDMSA-N (6ar,10ar)-9-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline Chemical compound C1=CC([C@@H]2[C@H](NCC(C2)C)C2)=C3C2=CNC3=C1 ZYACKOKSHZQYDS-NTVGDFDMSA-N 0.000 description 1
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
- JVLHFAZONCWQNP-UHFFFAOYSA-N 5-bromo-n-cyanopyridine-3-carboxamide Chemical compound BrC1=CN=CC(C(=O)NC#N)=C1 JVLHFAZONCWQNP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- OFTVILRGZVGOBF-MZMPZRCHSA-N CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=S)NC(C)=O Chemical compound CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=S)NC(C)=O OFTVILRGZVGOBF-MZMPZRCHSA-N 0.000 description 1
- SYSGZNVWWAYDFD-BSLALVQMSA-N CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=S)NC(C1=CC=CC=C1)=O Chemical compound CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CCNC(=S)NC(C1=CC=CC=C1)=O SYSGZNVWWAYDFD-BSLALVQMSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- VZMIIYFDQQAANA-SGIREYDYSA-N [(6ar,9s,10ar)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-yl]methanamine Chemical compound C1=CC([C@H]2C[C@@H](CN)CN([C@@H]2C2)C)=C3C2=CN(C)C3=C1 VZMIIYFDQQAANA-SGIREYDYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000026 anti-ulcerogenic effect Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- SONMPDKGILLKSF-FDQGKXFDSA-N n-[[(6ar,9s,10ar)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-yl]methylcarbamothioyl]acetamide Chemical compound C1=CC([C@H]2C[C@@H](CNC(=S)NC(C)=O)CN([C@@H]2C2)C)=C3C2=CN(C)C3=C1 SONMPDKGILLKSF-FDQGKXFDSA-N 0.000 description 1
- DBFAKALHTSOYSG-UHFFFAOYSA-N n-cyanobenzamide Chemical compound N#CNC(=O)C1=CC=CC=C1 DBFAKALHTSOYSG-UHFFFAOYSA-N 0.000 description 1
- HNKMOYMFMZSZGT-UHFFFAOYSA-N n-cyanopyridine-3-carboxamide Chemical compound N#CNC(=O)C1=CC=CN=C1 HNKMOYMFMZSZGT-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- LYULLJDMUFOQHU-UHFFFAOYSA-N propanoyl isothiocyanate Chemical compound CCC(=O)N=C=S LYULLJDMUFOQHU-UHFFFAOYSA-N 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
- C07D457/12—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8133631 | 1981-11-06 | ||
| GB8133631 | 1981-11-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5885886A JPS5885886A (ja) | 1983-05-23 |
| JPS628433B2 true JPS628433B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1987-02-23 |
Family
ID=10525712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57192620A Granted JPS5885886A (ja) | 1981-11-06 | 1982-11-04 | エルゴリン誘導体 |
Country Status (21)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3151912A1 (de) * | 1981-12-23 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel |
| PH21123A (en) * | 1983-04-28 | 1987-07-27 | Erba Farmitalia | Ergoline derivatives |
| DE3413657A1 (de) * | 1984-04-09 | 1985-10-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue ergoline |
| DE3587860D1 (de) * | 1984-04-09 | 1994-07-28 | Schering Ag | 2-substituierte Ergolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel. |
| GB2173189B (en) * | 1985-02-21 | 1988-04-27 | Maruko Pharmaceutical Co | Ergoline derivatives and salts thereof and pharmaceutical compositions thereof |
| GB8515528D0 (en) * | 1985-06-19 | 1985-07-24 | Erba Farmitalia | Ergoline derivatives |
| DE3528584A1 (de) * | 1985-08-06 | 1987-02-19 | Schering Ag | Neue 1-alkyl-ergolin-thioharnstoffderivate |
| DE3533672A1 (de) * | 1985-09-19 | 1987-03-26 | Schering Ag | Neue 12- und 13-substituierte ergolinderivate |
| DE3535930A1 (de) * | 1985-10-04 | 1987-04-09 | Schering Ag | Neue 2-substituierte ergolinderivate |
| DK0628042T3 (da) * | 1992-12-24 | 2001-11-12 | Pharmacia & Upjohn Spa | Serotoninerge ergolinderivater |
| DE19832191A1 (de) * | 1998-07-17 | 2000-01-27 | Knoell Hans Forschung Ev | Neuartige Ergolinamin-Derivate und ihre Verwendung |
| MXPA03011321A (es) | 2001-06-08 | 2004-12-06 | Conseils De Rech S Et D Aplica | Analogos quimericos de somatostatina-dopamina. |
| TW200637559A (en) * | 2005-03-29 | 2006-11-01 | Shionogi & Co | 3-propenylcefem derivative |
| TWI523863B (zh) | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | 體抑素－多巴胺嵌合體類似物 |
| JP2016503402A (ja) | 2012-11-01 | 2016-02-04 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | ソマトスタチン類似体及びそのダイマー |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238211A (en) * | 1966-03-01 | Derhvatives of g-methyl and i,g-dimethyl ergolhne | ||
| AT258479B (de) * | 1961-05-29 | 1967-11-27 | Farmaceutici Italia | Verfahren zur Herstellung von neuen Verbindungen aus der Klasse des D-6-Methyl- (und -1,6-Dimethyl)-8-amino-methyl-ergolins I |
| GB1005880A (en) * | 1961-11-10 | 1965-09-29 | Sandoz Ag | Ergolene and ergoline derivatives |
| GB1138419A (en) * | 1966-07-29 | 1969-01-01 | Farmaceutici Italia | Ergoline derivatives |
| BE712054A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1967-03-16 | 1968-07-15 | ||
| BR6915443D0 (pt) * | 1969-07-18 | 1973-03-13 | Farmaceutici Italia | Processo para a preparacao de derivados de ergolina |
| US3966941A (en) * | 1970-09-23 | 1976-06-29 | Spofa United Pharmaceutical Works | Composition for preventing lactation or pregnancy in mammals and the method for using the same |
| DK140596B (da) * | 1971-05-19 | 1979-10-08 | Sandoz Ag | Analogifremgangsmåde til fremstilling af 8beta-(ureidomethyl)-ergolenderivater. |
| NL7416120A (nl) * | 1973-12-21 | 1975-06-24 | Farmaceutici Italia | Werkwijze voor het bereiden van pyrimidinoami- nomethylergolinederivaten. |
| US3996228A (en) * | 1973-12-21 | 1976-12-07 | Societa' Farmaceutici Italia S.P.A. | Pyrimidinoaminoethyl ergoline derivatives |
| GB1573621A (en) * | 1976-01-02 | 1980-08-28 | Sandoz Ltd | Acylated 6-methyl-8a-amino-ergoline i compounds |
| DE2656344A1 (de) * | 1975-12-23 | 1977-07-07 | Sandoz Ag | Ergolinderivate, ihre verwendung und herstellung |
| HU178396B (en) * | 1978-03-20 | 1982-04-28 | Vianova Kunstharz Ag | Process for producing new 8-beta-hydrazion-methyl-ergoline-and -ergolene derivatives |
| DD138979A1 (de) * | 1978-09-27 | 1979-12-05 | Karlheinz Seifert | Verfahren zur herstellung von acylthioharnstoffen mit ergolinstruktur |
| US4201862A (en) * | 1979-03-16 | 1980-05-06 | Eli Lilly And Company | 2-Azaergolines and 2-aza-8(or 9)-ergolenes |
| DE3129714A1 (de) * | 1981-07-23 | 1983-02-10 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Anti-psychotikum |
-
1982
- 1982-10-29 GB GB08231053A patent/GB2112382B/en not_active Expired
- 1982-11-01 FI FI823727A patent/FI73214C/fi not_active IP Right Cessation
- 1982-11-01 CS CS827752A patent/CS232000B2/cs unknown
- 1982-11-01 SU SU823506255A patent/SU1189347A3/ru active
- 1982-11-01 US US06/438,259 patent/US4500712A/en not_active Expired - Fee Related
- 1982-11-01 NL NL8204225A patent/NL8204225A/nl not_active Application Discontinuation
- 1982-11-02 IL IL67155A patent/IL67155A/xx unknown
- 1982-11-02 AT AT0399682A patent/AT381091B/de not_active IP Right Cessation
- 1982-11-02 IE IE2614/82A patent/IE54327B1/en unknown
- 1982-11-02 AU AU90090/82A patent/AU553903B2/en not_active Ceased
- 1982-11-03 GR GR69718A patent/GR77055B/el unknown
- 1982-11-03 FR FR8218418A patent/FR2516083A1/fr active Granted
- 1982-11-04 SE SE8206282A patent/SE452884B/sv not_active IP Right Cessation
- 1982-11-04 IT IT24077/82A patent/IT1205272B/it active
- 1982-11-04 ZA ZA828095A patent/ZA828095B/xx unknown
- 1982-11-04 CA CA000414917A patent/CA1191841A/en not_active Expired
- 1982-11-04 DE DE19823240727 patent/DE3240727A1/de not_active Ceased
- 1982-11-04 JP JP57192620A patent/JPS5885886A/ja active Granted
- 1982-11-05 DK DK494882A patent/DK494882A/da not_active Application Discontinuation
- 1982-11-05 BE BE0/209409A patent/BE894927A/fr not_active IP Right Cessation
- 1982-11-05 CH CH6452/82A patent/CH650506A5/de not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS628433B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| HK89790A (en) | Novel carbostyril derivative and process for preparing same | |
| IE902657A1 (en) | New substituted 1H-indazole-3-carboxamides | |
| PL113082B1 (en) | Method of guanidine derivatives preparation | |
| SE446267B (sv) | Nya kinolylguanidinderivat, forfaranden for framstellning derav samt farmaceutiska kompositioner innehallande nemnda derivat | |
| CA2214744C (en) | 3-(bis-substituted phenylmethylene)oxindole derivatives | |
| US4404214A (en) | 2-Pyridinecarboxamide derivatives compositions containing same and method of using same | |
| US4432990A (en) | 5-Aminoimidazoles as immunoregulants | |
| US4141899A (en) | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives | |
| CA1110628A (en) | N-phenethylacetamide compounds and process for preparation thereof | |
| CA1085856A (en) | Pyrrolidine and piperidine prostaglandin analogues | |
| EP0329126B1 (en) | Heterocyclic compounds and antiulcer agents | |
| EP0223512B1 (en) | 2-pyridylacetic acid derivative, preparation process thereof and pharmaceutical composition containing the same | |
| CA1129417A (en) | Gastric acid secretion inhibiting substituted 2-(2- benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastricacid secretion | |
| CA1075240A (en) | 4,5,6,7-tetrahydroimidazo-(4,5-c)-pyridine derivatives | |
| AU7335898A (en) | 9,10-diazatricyclo{4.2.1.12,5}decane and 2,7-diazatricyclo{4.4.0.03,8}decane derivatives having analgesic activity | |
| GB2028798A (en) | 4,5,6,7-tetrahydromidazo(4,5-c)-pyridine derivatives | |
| KR850000062B1 (ko) | 아미딘의 제조방법 | |
| US4358452A (en) | N-[1,2,3,4,6,7,12,12 α-octahydro-2H-indolo(2,3α)-quinolizinyl-2β-yl]alkane and benzyl sulfonamides and anti-hypertensive use thereof | |
| HU186989B (en) | Process for preparing new ergoline derivatives | |
| JPH02178289A (ja) | イミダゾ［２，１―ｂ］チアゾール類 | |
| HU199134B (en) | Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same | |
| JPH01230560A (ja) | ベンズイミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤 | |
| CA1164464A (en) | Derivatives of indole active on the cardiovascular system | |
| JPH0414676B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |